[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fhr_ozmFHYshjkwWK5gQhtJ9oERr-hAmjaFdvXpybm5U":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":47,"rows":54},"Bial - Portela C S.A.",[4],136,false,2,13,12897,0,[13,16,19,22,25,28,31,33],{"name":14,"count":15},"Epilepsy",36,{"name":17,"count":18},"Parkinson Disease",31,{"name":20,"count":21},"Parkinson's Disease",14,{"name":23,"count":24},"Pulmonary Arterial Hypertension",12,{"name":26,"count":27},"Parkinson's Disease (PD)",11,{"name":29,"count":30},"Hypertension",6,{"name":32,"count":30},"Partial Epilepsy",{"name":34,"count":35},"Chronic Heart Failure",3,[37,42],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07145190","SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment","2028-02","SL-APO",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07403799","REal-life ON PARKinson's - ITaly (REONPARK-IT)","2028-10-31","Opicapone 50 mg",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,99,119,397,422,440,620,673,706,732,754,776,798,820,845,863,881,899,917,1120,1210,1245,1295,1329,1360,1382,1404,1430,1448,1466,1484,1502,1525,1543,1561,1585,1603,1621,1730,1783,1817,1847,1873,1895,1917,1939,1961,1989,2011,2029,2051,2069,2087,2114,2132,2150,2168,2186,2210,2231,2249,2267,2285,2303,2321,2339,2357,2375,2393,2411,2429,2447,2465,2483,2507,2525,2543,2561,2579,2601,2619,2642,2660,2682,2700,2722,2740,2758,2776,2802,2820,2838,2856,2874,2897,2915,2933,2951,2969,2987,3005,3023,3041,3065,3088,3106,3124,3175,3197],{"intervention":46,"totalTrials":35,"cells":56},{"EARLY_PHASE1":57,"PHASE1":59,"PHASE2":61,"PHASE3":63,"PHASE4":77,"NA":88},{"trials":58,"activeCount":11},[],{"trials":60,"activeCount":11},[],{"trials":62,"activeCount":11},[],{"trials":64,"activeCount":11},[65],{"nctId":66,"briefTitle":67,"status":68,"phases":69,"primaryCompletion":70,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":76},"NCT04978597","Early ParkinSon wIth L-DOPA\u002FDDCI and OpicapoNe (EPSILON Study)","COMPLETED",[51],"2023-01-11","2024-01-26","2021-05-31",410,[75],"Parkinson",[46],{"trials":78,"activeCount":11},[79],{"nctId":80,"briefTitle":81,"status":68,"phases":82,"primaryCompletion":83,"completion":83,"start":84,"enrollment":85,"conditions":86,"interventions":87},"NCT04986982","OpiCapone Effect on Motor Fluctuations and pAiN",[52],"2024-02-16","2021-02-25",144,[17],[46],{"trials":89,"activeCount":98,"soonestReadout":45},[90],{"nctId":43,"briefTitle":44,"status":91,"phases":92,"primaryCompletion":45,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":97},"RECRUITING",[],"2029-06-30","2025-07-08",200,[17],[46],1,{"intervention":41,"totalTrials":98,"cells":100},{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":111},{"trials":102,"activeCount":11},[],{"trials":104,"activeCount":11},[],{"trials":106,"activeCount":11},[],{"trials":108,"activeCount":11},[],{"trials":110,"activeCount":11},[],{"trials":112,"activeCount":98,"soonestReadout":40},[113],{"nctId":38,"briefTitle":39,"status":91,"phases":114,"primaryCompletion":40,"completion":40,"start":115,"enrollment":116,"conditions":117,"interventions":118},[],"2025-08-27",90,[17],[41],{"intervention":120,"totalTrials":121,"cells":122},"BIA 9-1067",29,{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":341,"PHASE3":360,"PHASE4":382,"NA":395},{"trials":124,"activeCount":11},[],{"trials":126,"activeCount":11},[127,136,146,156,164,175,184,194,202,212,220,230,239,247,257,265,274,282,289,298,306,314,323,333],{"nctId":128,"briefTitle":129,"status":68,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":135},"NCT02071810","Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067",[49],"2008-09","2008-04",34,[26],[120],{"nctId":137,"briefTitle":138,"status":68,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":144},"NCT03820037","Relative Bioavailability and Bioequivalence of Opicapone",[49],"2019-06-09","2019-03-19",45,[17],[145,120],"Ongentys",{"nctId":147,"briefTitle":148,"status":68,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":154},"NCT02169440","Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin",[49],"2009-07","2009-06",20,[26],[120,155],"Warfarin",{"nctId":157,"briefTitle":158,"status":68,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":152,"conditions":162,"interventions":163},"NCT02305030","Effect of Opicapone at Steady State on Warfarin Pharmacokinetics",[49],"2014-05","2014-03",[20],[120,155],{"nctId":165,"briefTitle":166,"status":68,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT02170376","The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics",[49],"2012-01","2011-09",80,[26],[120,173,174],"Entacapone","Levodopa\u002Fcarbidopa",{"nctId":176,"briefTitle":177,"status":68,"phases":178,"primaryCompletion":179,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":183},"NCT02101190","Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment",[49],"2010-05","2010-03",16,[20],[120],{"nctId":185,"briefTitle":186,"status":68,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":192},"NCT02169466","Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100\u002F25 mg Levodopa\u002FBenserazide",[49],"2009-05","2009-01",22,[26],[120,193],"Madopar® HBS",{"nctId":195,"briefTitle":196,"status":68,"phases":197,"primaryCompletion":189,"completion":189,"start":198,"enrollment":199,"conditions":200,"interventions":201},"NCT02092168","Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects",[49],"2008-10",24,[17],[120],{"nctId":203,"briefTitle":204,"status":68,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":199,"conditions":209,"interventions":210},"NCT01532128","Effect of BIA 9-1067 on Rasagiline Pharmacokinetics",[49],"2010-02","2010-07","2009-11",[17],[211,120],"rasagiline",{"nctId":213,"briefTitle":214,"status":68,"phases":215,"primaryCompletion":151,"completion":216,"start":188,"enrollment":217,"conditions":218,"interventions":219},"NCT01515891","Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites",[49],"2010-09",4,[17],[120],{"nctId":221,"briefTitle":222,"status":68,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":229},"NCT01520727","A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects",[49],"2007-12","2009-04","2007-10",64,[17],[120],{"nctId":231,"briefTitle":232,"status":68,"phases":233,"primaryCompletion":150,"completion":234,"start":151,"enrollment":235,"conditions":236,"interventions":237},"NCT01536366","Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide",[49],"2011-01",27,[17],[120,238],"Repaglinide",{"nctId":240,"briefTitle":241,"status":68,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":24,"conditions":245,"interventions":246},"NCT02071823","Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules",[49],"2008-06","2008-05",[75],[120],{"nctId":248,"briefTitle":249,"status":68,"phases":250,"primaryCompletion":251,"completion":206,"start":252,"enrollment":253,"conditions":254,"interventions":255},"NCT01533077","Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa\u002FCarbidopa",[49],"2009-10","2009-03",18,[17],[120,256],"Sinemet® 100\u002F25 mg",{"nctId":258,"briefTitle":259,"status":68,"phases":260,"primaryCompletion":261,"completion":261,"start":161,"enrollment":262,"conditions":263,"interventions":264},"NCT02305277","Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers",[49],"2014-06",85,[75],[120,120],{"nctId":266,"briefTitle":267,"status":68,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT02305329","Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation",[49],"2014-04","2014-02",56,[14],[120],{"nctId":275,"briefTitle":276,"status":68,"phases":277,"primaryCompletion":278,"completion":278,"start":131,"enrollment":181,"conditions":279,"interventions":280},"NCT02169479","Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100\u002F25 mg Levodopa\u002FCarbidopa",[49],"2008-12",[26],[120,281],"Sinemet® 100\u002F25",{"nctId":283,"briefTitle":284,"status":68,"phases":285,"primaryCompletion":189,"completion":189,"start":198,"enrollment":24,"conditions":286,"interventions":287},"NCT02169453","Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100\u002F25 mg Levodopa\u002FCarbidopa",[49],[26],[120,288],"Sinemet® CR 100\u002F25",{"nctId":290,"briefTitle":291,"status":68,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":297},"NCT01520987","Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects",[49],"2012-11","2011-05",105,[17],[120],{"nctId":299,"briefTitle":300,"status":68,"phases":301,"primaryCompletion":302,"completion":294,"start":179,"enrollment":227,"conditions":303,"interventions":304},"NCT01532115","Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women",[49],"2010-10",[17],[120,305],"moxifloxacin",{"nctId":307,"briefTitle":308,"status":68,"phases":309,"primaryCompletion":269,"completion":269,"start":161,"enrollment":310,"conditions":311,"interventions":312},"NCT02305017","Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers",[49],28,[20],[120,313],"Paracetamol",{"nctId":315,"briefTitle":316,"status":68,"phases":317,"primaryCompletion":206,"completion":318,"start":208,"enrollment":319,"conditions":320,"interventions":321},"NCT01532141","Effect of Rasagiline on BIA 9-1067 Pharmacokinetics",[49],"2010-08",25,[17],[120,322],"Rasagiline",{"nctId":324,"briefTitle":325,"status":68,"phases":326,"primaryCompletion":327,"completion":180,"start":252,"enrollment":328,"conditions":329,"interventions":330},"NCT01533116","Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa\u002FCarbidopa and Levodopa\u002FBenserazide",[49],"2009-08",52,[17],[120,331,332],"levodopa\u002Fcarbidopa","levodopa\u002Fbenserazide",{"nctId":334,"briefTitle":335,"status":68,"phases":336,"primaryCompletion":337,"completion":337,"start":131,"enrollment":181,"conditions":338,"interventions":339},"NCT02169895","Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa\u002FBenserazide",[49],"2008-11",[26],[120,340],"Prolopa®",{"trials":342,"activeCount":11},[343,352],{"nctId":344,"briefTitle":345,"status":68,"phases":346,"primaryCompletion":206,"completion":206,"start":225,"enrollment":347,"conditions":348,"interventions":349},"NCT01568034","A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067",[50],10,[20],[120,120,120,350,351],"Levodopa\u002FCarbidopa","Levodopa\u002FBenzerazide",{"nctId":353,"briefTitle":354,"status":68,"phases":355,"primaryCompletion":356,"completion":356,"start":206,"enrollment":357,"conditions":358,"interventions":359},"NCT01568047","Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients",[50],"2010-06",40,[20],[120,120,120,350,351],{"trials":361,"activeCount":11},[362,374],{"nctId":363,"briefTitle":364,"status":68,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT01227655","Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.",[51],"2012-07","2011-03",427,[20],[120,371,372,373],"Levodopa","Carbidopa","Benserazide",{"nctId":375,"briefTitle":376,"status":68,"phases":377,"primaryCompletion":378,"completion":378,"start":367,"enrollment":379,"conditions":380,"interventions":381},"NCT01568073","Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With \"Wearing-off\" Phenomenon",[51],"2013-11",600,[20],[120,173,371,372,373],{"trials":383,"activeCount":11},[384],{"nctId":385,"briefTitle":386,"status":68,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT02847442","Efficacy and Safety of Opicapone in Clinical Practice",[52],"2018-07-04","2016-11-23",518,[392],"Parkinson's Disease With Wearing-off Motor Fluctuations",[120,394],"levodopa\u002Fdopa decarboxylase inhibitor",{"trials":396,"activeCount":11},[],{"intervention":398,"totalTrials":98,"cells":399},"L-DOPA\u002FDDCI",{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":408,"NA":420},{"trials":401,"activeCount":11},[],{"trials":403,"activeCount":11},[],{"trials":405,"activeCount":11},[],{"trials":407,"activeCount":11},[],{"trials":409,"activeCount":11},[410],{"nctId":411,"briefTitle":412,"status":68,"phases":413,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":418},"NCT04990284","eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.",[52],"2023-04-04","2021-11-29",106,[17],[419,398],"Opicapone",{"trials":421,"activeCount":11},[],{"intervention":394,"totalTrials":98,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":438},{"trials":425,"activeCount":11},[],{"trials":427,"activeCount":11},[],{"trials":429,"activeCount":11},[],{"trials":431,"activeCount":11},[],{"trials":433,"activeCount":11},[434],{"nctId":385,"briefTitle":386,"status":68,"phases":435,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":436,"interventions":437},[52],[392],[120,394],{"trials":439,"activeCount":11},[],{"intervention":441,"totalTrials":253,"cells":442},"Eslicarbazepine acetate",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":499,"PHASE3":537,"PHASE4":616,"NA":618},{"trials":444,"activeCount":11},[],{"trials":446,"activeCount":11},[447,457,465,473,481,489],{"nctId":448,"briefTitle":449,"status":450,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":217,"conditions":454,"interventions":455},"NCT01878578","The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients","TERMINATED",[49],"2003-03","2002-11",[14],[441,456],"phenytoin",{"nctId":458,"briefTitle":459,"status":68,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":199,"conditions":463,"interventions":464},"NCT03116321","Bioequivalence of Two Different Sources of Eslicarbazepine Acetate",[49],"2017-01-05","2016-12-03",[14],[441],{"nctId":466,"briefTitle":467,"status":68,"phases":468,"primaryCompletion":224,"completion":131,"start":226,"enrollment":152,"conditions":469,"interventions":471},"NCT00971295","Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers",[49],[470],"Neuropathic Pain",[472,441],"Metformin",{"nctId":474,"briefTitle":475,"status":68,"phases":476,"primaryCompletion":327,"completion":327,"start":151,"enrollment":477,"conditions":478,"interventions":479},"NCT00987558","Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects",[49],30,[14],[441,480],"Simvastatin",{"nctId":482,"briefTitle":483,"status":68,"phases":484,"primaryCompletion":278,"completion":485,"start":337,"enrollment":21,"conditions":486,"interventions":487},"NCT00900237","Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine",[49],"2009-02",[32],[441,488],"Oxcarbazepine",{"nctId":490,"briefTitle":491,"status":68,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":497},"NCT02283801","Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.",[49],"2007-01","2006-11",32,[14],[441,498],"Lamotrigine",{"trials":500,"activeCount":11},[501,510,519,527],{"nctId":502,"briefTitle":503,"status":68,"phases":504,"primaryCompletion":505,"completion":506,"start":318,"enrollment":507,"conditions":508,"interventions":509},"NCT01527513","Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures",[50],"2012-03","2013-05",123,[32],[441],{"nctId":511,"briefTitle":512,"status":68,"phases":513,"primaryCompletion":189,"completion":189,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT00981227","Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia",[50],"2007-11",567,[517],"Postherpetic Neuralgia",[441],{"nctId":520,"briefTitle":521,"status":68,"phases":522,"primaryCompletion":337,"completion":337,"start":514,"enrollment":523,"conditions":524,"interventions":526},"NCT00980746","Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy",[50],557,[525],"Painful Diabetic Neuropathy",[441],{"nctId":528,"briefTitle":529,"status":68,"phases":530,"primaryCompletion":494,"completion":494,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT01822678","Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder",[50],"2005-12",161,[534],"Bipolar I Disorder",[536,536],"Eslicarbazepine Acetate",{"trials":538,"activeCount":11},[539,548,556,567,579,588,597,607],{"nctId":540,"briefTitle":541,"status":450,"phases":542,"primaryCompletion":543,"completion":543,"start":216,"enrollment":544,"conditions":545,"interventions":547},"NCT01124097","Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia",[51],"2012-04",240,[546],"Post Herpetic Neuralgia",[441],{"nctId":549,"briefTitle":550,"status":450,"phases":551,"primaryCompletion":543,"completion":543,"start":552,"enrollment":553,"conditions":554,"interventions":555},"NCT01129960","Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain",[51],"2010-11",332,[525],[441],{"nctId":557,"briefTitle":558,"status":68,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":566},"NCT00988156","Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children",[51],"2012-08-20","2017-08-24","2007-12-07",304,[565],"Partial Epilepsy in Children and Adolescents",[441,441],{"nctId":568,"briefTitle":569,"status":68,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":576},"NCT00957047","Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy",[51],"2006-08","2008-01","2004-07",395,[32],[577,578],"eslicarbazepine acetate","ESL - Part II",{"nctId":580,"briefTitle":581,"status":68,"phases":582,"primaryCompletion":243,"completion":243,"start":583,"enrollment":584,"conditions":585,"interventions":586},"NCT00957372","Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy",[51],"2004-12",253,[32],[577,587],"ESL - Open-label Extension",{"nctId":589,"briefTitle":590,"status":68,"phases":591,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":596},"NCT01422720","Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients",[51],"2013-09","2010-04",72,[14],[536],{"nctId":598,"briefTitle":599,"status":68,"phases":600,"primaryCompletion":601,"completion":602,"start":573,"enrollment":603,"conditions":604,"interventions":606},"NCT00957684","Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures",[51],"2005-11","2007-02",402,[605],"Refractory Partial Epilepsy",[577],{"nctId":608,"briefTitle":609,"status":68,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":615},"NCT01162460","Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures",[51],"2016-09","2010-12",815,[14],[441],{"trials":617,"activeCount":11},[],{"trials":619,"activeCount":11},[],{"intervention":621,"totalTrials":217,"cells":622},"ESL 800 mg",{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":657,"PHASE4":669,"NA":671},{"trials":624,"activeCount":11},[],{"trials":626,"activeCount":11},[],{"trials":628,"activeCount":11},[629,639,648],{"nctId":630,"briefTitle":631,"status":68,"phases":632,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":638},"NCT06597084","Anti-epileptogenic Effects of Eslicarbazepine Acetate",[50],"2023-09-11","2019-05-29",129,[637],"Post Stroke Epilepsy",[621],{"nctId":640,"briefTitle":641,"status":68,"phases":642,"primaryCompletion":356,"completion":356,"start":225,"enrollment":643,"conditions":644,"interventions":646},"NCT01820559","Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine",[50],452,[645],"Migraine",[647,621],"ESL 1200 mg",{"nctId":649,"briefTitle":650,"status":68,"phases":651,"primaryCompletion":216,"completion":216,"start":225,"enrollment":652,"conditions":653,"interventions":655},"NCT01820585","Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia",[50],528,[654],"Fibromyalgia",[656,621,647],"ESL 400 mg",{"trials":658,"activeCount":11},[659],{"nctId":660,"briefTitle":661,"status":68,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":667},"NCT02484001","Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures",[51],"2018-09-11","2016-03-01",206,[14],[621,647,668,656],"ESL 1600 mg",{"trials":670,"activeCount":11},[],{"trials":672,"activeCount":11},[],{"intervention":173,"totalTrials":35,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":694,"PHASE3":696,"PHASE4":702,"NA":704},{"trials":676,"activeCount":11},[],{"trials":678,"activeCount":11},[679,683],{"nctId":165,"briefTitle":166,"status":68,"phases":680,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":681,"interventions":682},[49],[26],[120,173,174],{"nctId":684,"briefTitle":685,"status":68,"phases":686,"primaryCompletion":206,"completion":687,"start":208,"enrollment":688,"conditions":689,"interventions":690},"NCT01519284","Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic",[49],"2011-06",82,[17],[691,173,331,692,693],"BIA 9-1067 5 mg","BIA 9-1067 15 mg","BIA 9-1067 30 mg",{"trials":695,"activeCount":11},[],{"trials":697,"activeCount":11},[698],{"nctId":375,"briefTitle":376,"status":68,"phases":699,"primaryCompletion":378,"completion":378,"start":367,"enrollment":379,"conditions":700,"interventions":701},[51],[20],[120,173,371,372,373],{"trials":703,"activeCount":11},[],{"trials":705,"activeCount":11},[],{"intervention":647,"totalTrials":35,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":722,"PHASE4":728,"NA":730},{"trials":709,"activeCount":11},[],{"trials":711,"activeCount":11},[],{"trials":713,"activeCount":11},[714,718],{"nctId":640,"briefTitle":641,"status":68,"phases":715,"primaryCompletion":356,"completion":356,"start":225,"enrollment":643,"conditions":716,"interventions":717},[50],[645],[647,621],{"nctId":649,"briefTitle":650,"status":68,"phases":719,"primaryCompletion":216,"completion":216,"start":225,"enrollment":652,"conditions":720,"interventions":721},[50],[654],[656,621,647],{"trials":723,"activeCount":11},[724],{"nctId":660,"briefTitle":661,"status":68,"phases":725,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":726,"interventions":727},[51],[14],[621,647,668,656],{"trials":729,"activeCount":11},[],{"trials":731,"activeCount":11},[],{"intervention":371,"totalTrials":8,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":750,"NA":752},{"trials":735,"activeCount":11},[],{"trials":737,"activeCount":11},[],{"trials":739,"activeCount":11},[],{"trials":741,"activeCount":11},[742,746],{"nctId":363,"briefTitle":364,"status":68,"phases":743,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":744,"interventions":745},[51],[20],[120,371,372,373],{"nctId":375,"briefTitle":376,"status":68,"phases":747,"primaryCompletion":378,"completion":378,"start":367,"enrollment":379,"conditions":748,"interventions":749},[51],[20],[120,173,371,372,373],{"trials":751,"activeCount":11},[],{"trials":753,"activeCount":11},[],{"intervention":372,"totalTrials":8,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":772,"NA":774},{"trials":757,"activeCount":11},[],{"trials":759,"activeCount":11},[],{"trials":761,"activeCount":11},[],{"trials":763,"activeCount":11},[764,768],{"nctId":363,"briefTitle":364,"status":68,"phases":765,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":766,"interventions":767},[51],[20],[120,371,372,373],{"nctId":375,"briefTitle":376,"status":68,"phases":769,"primaryCompletion":378,"completion":378,"start":367,"enrollment":379,"conditions":770,"interventions":771},[51],[20],[120,173,371,372,373],{"trials":773,"activeCount":11},[],{"trials":775,"activeCount":11},[],{"intervention":373,"totalTrials":8,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":794,"NA":796},{"trials":779,"activeCount":11},[],{"trials":781,"activeCount":11},[],{"trials":783,"activeCount":11},[],{"trials":785,"activeCount":11},[786,790],{"nctId":363,"briefTitle":364,"status":68,"phases":787,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":788,"interventions":789},[51],[20],[120,371,372,373],{"nctId":375,"briefTitle":376,"status":68,"phases":791,"primaryCompletion":378,"completion":378,"start":367,"enrollment":379,"conditions":792,"interventions":793},[51],[20],[120,173,371,372,373],{"trials":795,"activeCount":11},[],{"trials":797,"activeCount":11},[],{"intervention":656,"totalTrials":8,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":810,"PHASE4":816,"NA":818},{"trials":801,"activeCount":11},[],{"trials":803,"activeCount":11},[],{"trials":805,"activeCount":11},[806],{"nctId":649,"briefTitle":650,"status":68,"phases":807,"primaryCompletion":216,"completion":216,"start":225,"enrollment":652,"conditions":808,"interventions":809},[50],[654],[656,621,647],{"trials":811,"activeCount":11},[812],{"nctId":660,"briefTitle":661,"status":68,"phases":813,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":814,"interventions":815},[51],[14],[621,647,668,656],{"trials":817,"activeCount":11},[],{"trials":819,"activeCount":11},[],{"intervention":821,"totalTrials":98,"cells":822},"800 mg QD Eslicarbazepine acetate",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":841,"NA":843},{"trials":824,"activeCount":11},[],{"trials":826,"activeCount":11},[],{"trials":828,"activeCount":11},[],{"trials":830,"activeCount":11},[831],{"nctId":832,"briefTitle":833,"status":68,"phases":834,"primaryCompletion":835,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":839},"NCT00988429","Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures",[51],"2012-01-12","2008-12-02",653,[32],[821,840],"1200 mg QD Eslicarbazepine acetate",{"trials":842,"activeCount":11},[],{"trials":844,"activeCount":11},[],{"intervention":840,"totalTrials":98,"cells":846},{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":853,"PHASE4":859,"NA":861},{"trials":848,"activeCount":11},[],{"trials":850,"activeCount":11},[],{"trials":852,"activeCount":11},[],{"trials":854,"activeCount":11},[855],{"nctId":832,"briefTitle":833,"status":68,"phases":856,"primaryCompletion":835,"completion":835,"start":836,"enrollment":837,"conditions":857,"interventions":858},[51],[32],[821,840],{"trials":860,"activeCount":11},[],{"trials":862,"activeCount":11},[],{"intervention":668,"totalTrials":98,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":877,"NA":879},{"trials":866,"activeCount":11},[],{"trials":868,"activeCount":11},[],{"trials":870,"activeCount":11},[],{"trials":872,"activeCount":11},[873],{"nctId":660,"briefTitle":661,"status":68,"phases":874,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":875,"interventions":876},[51],[14],[621,647,668,656],{"trials":878,"activeCount":11},[],{"trials":880,"activeCount":11},[],{"intervention":578,"totalTrials":98,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":895,"NA":897},{"trials":884,"activeCount":11},[],{"trials":886,"activeCount":11},[],{"trials":888,"activeCount":11},[],{"trials":890,"activeCount":11},[891],{"nctId":568,"briefTitle":569,"status":68,"phases":892,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":893,"interventions":894},[51],[32],[577,578],{"trials":896,"activeCount":11},[],{"trials":898,"activeCount":11},[],{"intervention":587,"totalTrials":98,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":913,"NA":915},{"trials":902,"activeCount":11},[],{"trials":904,"activeCount":11},[],{"trials":906,"activeCount":11},[],{"trials":908,"activeCount":11},[909],{"nctId":580,"briefTitle":581,"status":68,"phases":910,"primaryCompletion":243,"completion":243,"start":583,"enrollment":584,"conditions":911,"interventions":912},[51],[32],[577,587],{"trials":914,"activeCount":11},[],{"trials":916,"activeCount":11},[],{"intervention":918,"totalTrials":199,"cells":919},"BIA 2-093",{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":1097,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":921,"activeCount":11},[],{"trials":923,"activeCount":11},[924,934,941,947,955,963,970,978,986,994,1002,1010,1017,1025,1033,1041,1049,1057,1065,1072,1081,1089],{"nctId":925,"briefTitle":926,"status":68,"phases":927,"primaryCompletion":928,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":932},"NCT02283788","Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization",[49],"2007-06","2007-03",67,[14],[918,933],"Moxifloxacin",{"nctId":935,"briefTitle":936,"status":68,"phases":937,"primaryCompletion":929,"completion":929,"start":493,"enrollment":495,"conditions":938,"interventions":939},"NCT02283827","Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.",[49],[14],[918,940],"Phenytoin",{"nctId":942,"briefTitle":943,"status":68,"phases":944,"primaryCompletion":552,"completion":552,"start":302,"enrollment":357,"conditions":945,"interventions":946},"NCT02284880","Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate",[49],[14],[918,918],{"nctId":948,"briefTitle":949,"status":68,"phases":950,"primaryCompletion":951,"completion":951,"start":952,"enrollment":357,"conditions":953,"interventions":954},"NCT02281422","An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093",[49],"2006-06","2005-03",[14],[918],{"nctId":956,"briefTitle":957,"status":68,"phases":958,"primaryCompletion":928,"completion":928,"start":959,"enrollment":960,"conditions":961,"interventions":962},"NCT02283840","Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation",[49],"2007-05",60,[14],[918],{"nctId":964,"briefTitle":965,"status":68,"phases":966,"primaryCompletion":602,"completion":602,"start":493,"enrollment":495,"conditions":967,"interventions":968},"NCT02283814","A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate",[49],[14],[918,969],"Topamax",{"nctId":971,"briefTitle":972,"status":68,"phases":973,"primaryCompletion":974,"completion":974,"start":952,"enrollment":152,"conditions":975,"interventions":976},"NCT02281448","Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.",[49],"2005-05",[14],[918,977],"Contraceptives, Oral, Combined",{"nctId":979,"briefTitle":980,"status":68,"phases":981,"primaryCompletion":514,"completion":514,"start":982,"enrollment":983,"conditions":984,"interventions":985},"NCT02284828","Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function",[49],"2007-09",26,[14],[918],{"nctId":987,"briefTitle":988,"status":68,"phases":989,"primaryCompletion":990,"completion":990,"start":991,"enrollment":24,"conditions":992,"interventions":993},"NCT02170649","The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093",[49],"2001-11","2001-09",[14],[918],{"nctId":995,"briefTitle":996,"status":68,"phases":997,"primaryCompletion":998,"completion":998,"start":999,"enrollment":9,"conditions":1000,"interventions":1001},"NCT02287415","The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin",[49],"2002-07","2002-05",[14],[918,155],{"nctId":1003,"briefTitle":1004,"status":68,"phases":1005,"primaryCompletion":1006,"completion":1006,"start":1007,"enrollment":253,"conditions":1008,"interventions":1009},"NCT02279667","Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093",[49],"2004-03","2004-02",[14],[918,918,918],{"nctId":1011,"briefTitle":1012,"status":68,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":959,"enrollment":253,"conditions":1015,"interventions":1016},"NCT02288312","Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate",[49],"2007-07",[14],[918],{"nctId":1018,"briefTitle":1019,"status":68,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":477,"conditions":1023,"interventions":1024},"NCT02172755","Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites",[49],"2002-08","2002-06",[14],[918],{"nctId":1026,"briefTitle":1027,"status":68,"phases":1028,"primaryCompletion":1029,"completion":1029,"start":974,"enrollment":1030,"conditions":1031,"interventions":1032},"NCT02281526","An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093",[49],"2006-02",17,[14],[918],{"nctId":1034,"briefTitle":1035,"status":68,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":24,"conditions":1039,"interventions":1040},"NCT01679002","Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers",[49],"2003-12","2003-10",[14],[918,488],{"nctId":1042,"briefTitle":1043,"status":68,"phases":1044,"primaryCompletion":1045,"completion":1045,"start":1046,"enrollment":9,"conditions":1047,"interventions":1048},"NCT01678976","Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers",[49],"2002-04","2002-03",[14],[918,488],{"nctId":1050,"briefTitle":1051,"status":68,"phases":1052,"primaryCompletion":1053,"completion":1053,"start":1054,"enrollment":495,"conditions":1055,"interventions":1056},"NCT02171234","A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093",[49],"2001-06","2001-02",[14],[918],{"nctId":1058,"briefTitle":1059,"status":68,"phases":1060,"primaryCompletion":998,"completion":1061,"start":999,"enrollment":9,"conditions":1062,"interventions":1063},"NCT02172742","The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin",[49],"2002-07-25",[14],[918,1064],"Digoxin",{"nctId":1066,"briefTitle":1067,"status":68,"phases":1068,"primaryCompletion":224,"completion":224,"start":226,"enrollment":152,"conditions":1069,"interventions":1070},"NCT02777671","Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers",[49],[14],[918,1071],"Gliclazide",{"nctId":1073,"briefTitle":1074,"status":68,"phases":1075,"primaryCompletion":1076,"completion":1076,"start":951,"enrollment":495,"conditions":1077,"interventions":1078},"NCT02281591","Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine",[49],"2006-07",[14],[918,1079,1080],"S-licarbazepine","R-licarbazepine",{"nctId":1082,"briefTitle":1083,"status":68,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":227,"conditions":1087,"interventions":1088},"NCT02171195","A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093",[49],"2000-10","2000-07",[14],[918],{"nctId":1090,"briefTitle":1091,"status":68,"phases":1092,"primaryCompletion":208,"completion":208,"start":150,"enrollment":1093,"conditions":1094,"interventions":1095},"NCT02284854","Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine",[49],43,[14],[918,1096],"Carbamazepine",{"trials":1098,"activeCount":11},[1099,1108],{"nctId":1100,"briefTitle":1101,"status":68,"phases":1102,"primaryCompletion":1103,"completion":1103,"start":1104,"enrollment":1105,"conditions":1106,"interventions":1107},"NCT02170064","Pharmacokinetics, Efficacy and Tolerability of BIA 2-093",[50],"2006-04","2005-06",35,[14],[918],{"nctId":1109,"briefTitle":1110,"status":68,"phases":1111,"primaryCompletion":453,"completion":453,"start":1045,"enrollment":85,"conditions":1112,"interventions":1113},"NCT02170077","A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093",[50],[14],[918],{"trials":1115,"activeCount":11},[],{"trials":1117,"activeCount":11},[],{"trials":1119,"activeCount":11},[],{"intervention":1121,"totalTrials":1122,"cells":1123},"BIA 3-202",9,{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1195,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1125,"activeCount":11},[],{"trials":1127,"activeCount":11},[1128,1136,1143,1150,1160,1169,1179,1186],{"nctId":1129,"briefTitle":1130,"status":68,"phases":1131,"primaryCompletion":601,"completion":601,"start":1132,"enrollment":1030,"conditions":1133,"interventions":1134},"NCT02778594","Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa\u002FBenserazide",[49],"2005-09",[26],[1121,1135],"levodopa 100 mg \u002F benserazide 25 mg",{"nctId":1137,"briefTitle":1138,"status":68,"phases":1139,"primaryCompletion":601,"completion":601,"start":1132,"enrollment":181,"conditions":1140,"interventions":1141},"NCT02774564","Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa\u002FCarbidopa",[49],[20],[1121,1142],"Sinemet®",{"nctId":1144,"briefTitle":1145,"status":68,"phases":1146,"primaryCompletion":1029,"completion":1029,"start":1147,"enrollment":217,"conditions":1148,"interventions":1149},"NCT02772614","Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites",[49],"2006-01",[20],[1121],{"nctId":1151,"briefTitle":1152,"status":68,"phases":1153,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":181,"conditions":1156,"interventions":1158},"NCT02779348","Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin",[49],"2006-12","2006-09",[1157],"Healthy",[1121,1159],"warfarin",{"nctId":1161,"briefTitle":1162,"status":68,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":1165,"enrollment":1166,"conditions":1167,"interventions":1168},"NCT02763787","Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202",[49],"2000-06","2000-04",71,[20],[1121],{"nctId":1170,"briefTitle":1171,"status":68,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1177},"NCT02763839","Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa\u002FCarbidopa (100\u002F25 mg)",[49],"2001-07","2001-04",19,[20],[1121,1178],"Sinemet 25\u002F100",{"nctId":1180,"briefTitle":1181,"status":68,"phases":1182,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":253,"conditions":1183,"interventions":1184},"NCT02763852","Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa\u002FBenserazide (100\u002F25 mg)",[49],[20],[1121,1185],"Madopar® 125",{"nctId":1187,"briefTitle":1188,"status":68,"phases":1189,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1194},"NCT02763800","Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202",[49],"2001-01","2000-09",33,[20],[1121],{"trials":1196,"activeCount":11},[1197],{"nctId":1198,"briefTitle":1199,"status":68,"phases":1200,"primaryCompletion":601,"completion":601,"start":952,"enrollment":1175,"conditions":1201,"interventions":1202},"NCT02834507","Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients",[50],[26],[1121,1203,1142],"Comtan®",{"trials":1205,"activeCount":11},[],{"trials":1207,"activeCount":11},[],{"trials":1209,"activeCount":11},[],{"intervention":331,"totalTrials":1211,"cells":1212},5,{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1229,"PHASE3":1239,"PHASE4":1241,"NA":1243},{"trials":1214,"activeCount":11},[],{"trials":1216,"activeCount":11},[1217,1221,1225],{"nctId":165,"briefTitle":166,"status":68,"phases":1218,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":1219,"interventions":1220},[49],[26],[120,173,174],{"nctId":684,"briefTitle":685,"status":68,"phases":1222,"primaryCompletion":206,"completion":687,"start":208,"enrollment":688,"conditions":1223,"interventions":1224},[49],[17],[691,173,331,692,693],{"nctId":324,"briefTitle":325,"status":68,"phases":1226,"primaryCompletion":327,"completion":180,"start":252,"enrollment":328,"conditions":1227,"interventions":1228},[49],[17],[120,331,332],{"trials":1230,"activeCount":11},[1231,1235],{"nctId":344,"briefTitle":345,"status":68,"phases":1232,"primaryCompletion":206,"completion":206,"start":225,"enrollment":347,"conditions":1233,"interventions":1234},[50],[20],[120,120,120,350,351],{"nctId":353,"briefTitle":354,"status":68,"phases":1236,"primaryCompletion":356,"completion":356,"start":206,"enrollment":357,"conditions":1237,"interventions":1238},[50],[20],[120,120,120,350,351],{"trials":1240,"activeCount":11},[],{"trials":1242,"activeCount":11},[],{"trials":1244,"activeCount":11},[],{"intervention":1203,"totalTrials":217,"cells":1246},{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1272,"PHASE3":1289,"PHASE4":1291,"NA":1293},{"trials":1248,"activeCount":11},[],{"trials":1250,"activeCount":11},[1251,1261],{"nctId":1252,"briefTitle":1253,"status":68,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":170,"conditions":1257,"interventions":1258},"NCT03091868","Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics",[49],"2005-02-28","2004-11-03",[17],[281,1203,1259,1260],"BIA 6-512 25 mg","BIA 6-512 100 mg",{"nctId":1262,"briefTitle":1263,"status":68,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1269},"NCT03094156","Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics",[49],"2006-07-11","2006-04-26",39,[17],[1270,1271,1203],"BIA 6-512","Madopar® 250",{"trials":1273,"activeCount":11},[1274,1285],{"nctId":1275,"briefTitle":1276,"status":68,"phases":1277,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1282},"NCT03103399","Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With \"Wearingoff\" Phenomenon",[50],"2007-09-21","2006-09-26",254,[17],[1203,1283,1284],"Nebicapone","Levodopa\u002FDDCI",{"nctId":1198,"briefTitle":1199,"status":68,"phases":1286,"primaryCompletion":601,"completion":601,"start":952,"enrollment":1175,"conditions":1287,"interventions":1288},[50],[26],[1121,1203,1142],{"trials":1290,"activeCount":11},[],{"trials":1292,"activeCount":11},[],{"trials":1294,"activeCount":11},[],{"intervention":1283,"totalTrials":35,"cells":1296},{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1317,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1298,"activeCount":11},[],{"trials":1300,"activeCount":11},[1301,1310],{"nctId":1302,"briefTitle":1303,"status":68,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1309},"NCT03097211","Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa\u002FBenserazide 200\u002F50 mg or With a Single-dose of Levodopa\u002FBenserazide 200\u002F50 mg Plus a Single-dose of Nebicapone 150 mg",[49],"2006-10-20","2006-07-17",38,[17],[1270,1271,1283],{"nctId":1311,"briefTitle":1312,"status":68,"phases":1313,"primaryCompletion":1314,"completion":1314,"start":991,"enrollment":190,"conditions":1315,"interventions":1316},"NCT02772627","Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202",[49],"2001-12",[20],[1283],{"trials":1318,"activeCount":11},[1319],{"nctId":1275,"briefTitle":1276,"status":68,"phases":1320,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":1321,"interventions":1322},[50],[17],[1203,1283,1284],{"trials":1324,"activeCount":11},[],{"trials":1326,"activeCount":11},[],{"trials":1328,"activeCount":11},[],{"intervention":1330,"totalTrials":8,"cells":1331},"Oral zamicastat",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1354,"PHASE4":1356,"NA":1358},{"trials":1333,"activeCount":11},[],{"trials":1335,"activeCount":11},[],{"trials":1337,"activeCount":11},[1338,1346],{"nctId":1339,"briefTitle":1340,"status":68,"phases":1341,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":152,"conditions":1344,"interventions":1345},"NCT06009185","Safety and Efficacy of BIA 5-1058 in PAH",[50],"2022-02-17","2019-06-26",[23],[1330],{"nctId":1347,"briefTitle":1348,"status":68,"phases":1349,"primaryCompletion":1350,"completion":1350,"start":1351,"enrollment":1192,"conditions":1352,"interventions":1353},"NCT04316143","Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)",[50],"2021-10-20","2019-06-03",[23],[1330],{"trials":1355,"activeCount":11},[],{"trials":1357,"activeCount":11},[],{"trials":1359,"activeCount":11},[],{"intervention":1142,"totalTrials":8,"cells":1361},{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1370,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1363,"activeCount":11},[],{"trials":1365,"activeCount":11},[1366],{"nctId":1137,"briefTitle":1138,"status":68,"phases":1367,"primaryCompletion":601,"completion":601,"start":1132,"enrollment":181,"conditions":1368,"interventions":1369},[49],[20],[1121,1142],{"trials":1371,"activeCount":11},[1372],{"nctId":1198,"briefTitle":1199,"status":68,"phases":1373,"primaryCompletion":601,"completion":601,"start":952,"enrollment":1175,"conditions":1374,"interventions":1375},[50],[26],[1121,1203,1142],{"trials":1377,"activeCount":11},[],{"trials":1379,"activeCount":11},[],{"trials":1381,"activeCount":11},[],{"intervention":351,"totalTrials":8,"cells":1383},{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1398,"PHASE4":1400,"NA":1402},{"trials":1385,"activeCount":11},[],{"trials":1387,"activeCount":11},[],{"trials":1389,"activeCount":11},[1390,1394],{"nctId":344,"briefTitle":345,"status":68,"phases":1391,"primaryCompletion":206,"completion":206,"start":225,"enrollment":347,"conditions":1392,"interventions":1393},[50],[20],[120,120,120,350,351],{"nctId":353,"briefTitle":354,"status":68,"phases":1395,"primaryCompletion":356,"completion":356,"start":206,"enrollment":357,"conditions":1396,"interventions":1397},[50],[20],[120,120,120,350,351],{"trials":1399,"activeCount":11},[],{"trials":1401,"activeCount":11},[],{"trials":1403,"activeCount":11},[],{"intervention":1405,"totalTrials":98,"cells":1406},"BIA 2-093 1800 mg once daily [Group 1 (Part II)]",{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1411,"PHASE3":1424,"PHASE4":1426,"NA":1428},{"trials":1408,"activeCount":11},[],{"trials":1410,"activeCount":11},[],{"trials":1412,"activeCount":11},[1413],{"nctId":1414,"briefTitle":1415,"status":68,"phases":1416,"primaryCompletion":928,"completion":928,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1420},"NCT01825837","Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder",[50],"2006-03",104,[534],[1405,1421,1422,1423],"BIA 2-093 900 mg once daily [Group 2 (Part II)]","BIA 2-093 300 mg once daily [Group 3 (Part II)]","BIA 2-093 900 mg",{"trials":1425,"activeCount":11},[],{"trials":1427,"activeCount":11},[],{"trials":1429,"activeCount":11},[],{"intervention":1421,"totalTrials":98,"cells":1431},{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1433,"activeCount":11},[],{"trials":1435,"activeCount":11},[],{"trials":1437,"activeCount":11},[1438],{"nctId":1414,"briefTitle":1415,"status":68,"phases":1439,"primaryCompletion":928,"completion":928,"start":1417,"enrollment":1418,"conditions":1440,"interventions":1441},[50],[534],[1405,1421,1422,1423],{"trials":1443,"activeCount":11},[],{"trials":1445,"activeCount":11},[],{"trials":1447,"activeCount":11},[],{"intervention":1422,"totalTrials":98,"cells":1449},{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1460,"PHASE4":1462,"NA":1464},{"trials":1451,"activeCount":11},[],{"trials":1453,"activeCount":11},[],{"trials":1455,"activeCount":11},[1456],{"nctId":1414,"briefTitle":1415,"status":68,"phases":1457,"primaryCompletion":928,"completion":928,"start":1417,"enrollment":1418,"conditions":1458,"interventions":1459},[50],[534],[1405,1421,1422,1423],{"trials":1461,"activeCount":11},[],{"trials":1463,"activeCount":11},[],{"trials":1465,"activeCount":11},[],{"intervention":1423,"totalTrials":98,"cells":1467},{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1478,"PHASE4":1480,"NA":1482},{"trials":1469,"activeCount":11},[],{"trials":1471,"activeCount":11},[],{"trials":1473,"activeCount":11},[1474],{"nctId":1414,"briefTitle":1415,"status":68,"phases":1475,"primaryCompletion":928,"completion":928,"start":1417,"enrollment":1418,"conditions":1476,"interventions":1477},[50],[534],[1405,1421,1422,1423],{"trials":1479,"activeCount":11},[],{"trials":1481,"activeCount":11},[],{"trials":1483,"activeCount":11},[],{"intervention":1284,"totalTrials":98,"cells":1485},{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1496,"PHASE4":1498,"NA":1500},{"trials":1487,"activeCount":11},[],{"trials":1489,"activeCount":11},[],{"trials":1491,"activeCount":11},[1492],{"nctId":1275,"briefTitle":1276,"status":68,"phases":1493,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":1280,"conditions":1494,"interventions":1495},[50],[17],[1203,1283,1284],{"trials":1497,"activeCount":11},[],{"trials":1499,"activeCount":11},[],{"trials":1501,"activeCount":11},[],{"intervention":1503,"totalTrials":98,"cells":1504},"Eslicarbazepine acetate 1800 mg",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1506,"activeCount":11},[],{"trials":1508,"activeCount":11},[],{"trials":1510,"activeCount":11},[1511],{"nctId":1512,"briefTitle":529,"status":450,"phases":1513,"primaryCompletion":494,"completion":494,"start":1029,"enrollment":1307,"conditions":1514,"interventions":1516},"NCT01824602",[50],[1515],"BIPOLAR I DISORDER",[1503,1517,1518],"Eslicarbazepine acetate 1200 mg","Eslicarbazepine acetate 600 mg",{"trials":1520,"activeCount":11},[],{"trials":1522,"activeCount":11},[],{"trials":1524,"activeCount":11},[],{"intervention":1517,"totalTrials":98,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":11},[],{"trials":1530,"activeCount":11},[],{"trials":1532,"activeCount":11},[1533],{"nctId":1512,"briefTitle":529,"status":450,"phases":1534,"primaryCompletion":494,"completion":494,"start":1029,"enrollment":1307,"conditions":1535,"interventions":1536},[50],[1515],[1503,1517,1518],{"trials":1538,"activeCount":11},[],{"trials":1540,"activeCount":11},[],{"trials":1542,"activeCount":11},[],{"intervention":1518,"totalTrials":98,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1555,"PHASE4":1557,"NA":1559},{"trials":1546,"activeCount":11},[],{"trials":1548,"activeCount":11},[],{"trials":1550,"activeCount":11},[1551],{"nctId":1512,"briefTitle":529,"status":450,"phases":1552,"primaryCompletion":494,"completion":494,"start":1029,"enrollment":1307,"conditions":1553,"interventions":1554},[50],[1515],[1503,1517,1518],{"trials":1556,"activeCount":11},[],{"trials":1558,"activeCount":11},[],{"trials":1560,"activeCount":11},[],{"intervention":1562,"totalTrials":98,"cells":1563},"ESL Banana taste",{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1565,"activeCount":11},[],{"trials":1567,"activeCount":11},[],{"trials":1569,"activeCount":11},[1570],{"nctId":1571,"briefTitle":1572,"status":68,"phases":1573,"primaryCompletion":1574,"completion":1574,"start":1574,"enrollment":1307,"conditions":1575,"interventions":1576},"NCT02021461","Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours",[50],"2012-12",[14],[1562,1577,1578],"ESL Grape taste","ESL Tutti-Frutti taste",{"trials":1580,"activeCount":11},[],{"trials":1582,"activeCount":11},[],{"trials":1584,"activeCount":11},[],{"intervention":1577,"totalTrials":98,"cells":1586},{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1588,"activeCount":11},[],{"trials":1590,"activeCount":11},[],{"trials":1592,"activeCount":11},[1593],{"nctId":1571,"briefTitle":1572,"status":68,"phases":1594,"primaryCompletion":1574,"completion":1574,"start":1574,"enrollment":1307,"conditions":1595,"interventions":1596},[50],[14],[1562,1577,1578],{"trials":1598,"activeCount":11},[],{"trials":1600,"activeCount":11},[],{"trials":1602,"activeCount":11},[],{"intervention":1578,"totalTrials":98,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1615,"PHASE4":1617,"NA":1619},{"trials":1606,"activeCount":11},[],{"trials":1608,"activeCount":11},[],{"trials":1610,"activeCount":11},[1611],{"nctId":1571,"briefTitle":1572,"status":68,"phases":1612,"primaryCompletion":1574,"completion":1574,"start":1574,"enrollment":1307,"conditions":1613,"interventions":1614},[50],[14],[1562,1577,1578],{"trials":1616,"activeCount":11},[],{"trials":1618,"activeCount":11},[],{"trials":1620,"activeCount":11},[],{"intervention":1622,"totalTrials":347,"cells":1623},"BIA 5-1058",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1722,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1625,"activeCount":11},[],{"trials":1627,"activeCount":11},[1628,1638,1647,1656,1665,1675,1683,1693,1702,1714],{"nctId":1629,"briefTitle":1630,"status":68,"phases":1631,"primaryCompletion":1632,"completion":1632,"start":1633,"enrollment":1634,"conditions":1635,"interventions":1636},"NCT04991207","Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan",[49],"2018-05-14","2018-02-06",44,[23],[1622,1637],"bosentan",{"nctId":1639,"briefTitle":1640,"status":68,"phases":1641,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":152,"conditions":1644,"interventions":1645},"NCT04675944","Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil",[49],"2018-05-25","2018-02-28",[23],[1622,1646],"treprostinil",{"nctId":1648,"briefTitle":1649,"status":450,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1655},"NCT04991194","Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058",[49],"2016-12-30","2015-10-12",61,[23],[1622],{"nctId":1657,"briefTitle":1658,"status":68,"phases":1659,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":152,"conditions":1662,"interventions":1663},"NCT04994860","Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil",[49],"2018-06-07","2018-03-22",[23],[1622,1664],"Sildenafil",{"nctId":1666,"briefTitle":1667,"status":68,"phases":1668,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":1634,"conditions":1671,"interventions":1672},"NCT07173738","Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide",[49],"2018-09-07","2018-06-11",[23],[1622,1673,1674],"Furosemide","BIA 5-1058 and Furosemide",{"nctId":1676,"briefTitle":1677,"status":68,"phases":1678,"primaryCompletion":1679,"completion":1679,"start":1680,"enrollment":983,"conditions":1681,"interventions":1682},"NCT04994119","Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics",[49],"2018-05-23","2018-02-23",[23],[1622,155],{"nctId":1684,"briefTitle":1685,"status":68,"phases":1686,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":1689,"conditions":1690,"interventions":1692},"NCT03708146","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058",[49],"2019-03-18","2018-05-28",157,[1691,23],"Cardiovascular Disease+Pulmonary Disease",[1622],{"nctId":1694,"briefTitle":1695,"status":68,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1701},"NCT04991155","Effect of Food on BIA 5-1058",[49],"2015-09-22","2015-07-20",57,[23],[1622],{"nctId":1703,"briefTitle":1704,"status":68,"phases":1705,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1709,"interventions":1712},"NCT03489005","Effect of BIA 5 1058 on Cardiac Repolarization",[49],"2018-10-05","2018-04-09",49,[1710,23,1711],"Cardiovascular Disease","Heart Failure",[1622,1713],"Moxifloxacin 400 mg",{"nctId":1715,"briefTitle":1716,"status":68,"phases":1717,"primaryCompletion":168,"completion":168,"start":367,"enrollment":1718,"conditions":1719,"interventions":1721},"NCT02151994","Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.",[49],124,[1720],"Hypertension and Chronic Heart Failure",[1622],{"trials":1723,"activeCount":11},[],{"trials":1725,"activeCount":11},[],{"trials":1727,"activeCount":11},[],{"trials":1729,"activeCount":11},[],{"intervention":1731,"totalTrials":1211,"cells":1732},"BIA 5-453",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1775,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1734,"activeCount":11},[],{"trials":1736,"activeCount":11},[1737,1743,1752,1760,1768],{"nctId":1738,"briefTitle":1739,"status":68,"phases":1740,"primaryCompletion":982,"completion":982,"start":959,"enrollment":170,"conditions":1741,"interventions":1742},"NCT02845037","Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453",[49],[29,34],[1731],{"nctId":1744,"briefTitle":1745,"status":68,"phases":1746,"primaryCompletion":1747,"completion":1747,"start":1748,"enrollment":1749,"conditions":1750,"interventions":1751},"NCT03099226","Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453",[49],"2009-04-03","2008-07-15",23,[29],[1731],{"nctId":1753,"briefTitle":1754,"status":68,"phases":1755,"primaryCompletion":1756,"completion":1756,"start":1748,"enrollment":24,"conditions":1757,"interventions":1759},"NCT03090568","Bioavailability Study of BIA 5-453",[49],"2008-08-14",[29,1758],"Congestive Heart Failure",[1731],{"nctId":1761,"briefTitle":1762,"status":68,"phases":1763,"primaryCompletion":1764,"completion":1764,"start":1765,"enrollment":319,"conditions":1766,"interventions":1767},"NCT03090724","Pharmacokinetics of BIA 5-453 and Its Metabolites",[49],"2008-08-12","2008-06-13",[29,34],[1731],{"nctId":1769,"briefTitle":1770,"status":68,"phases":1771,"primaryCompletion":1772,"completion":1772,"start":982,"enrollment":1699,"conditions":1773,"interventions":1774},"NCT02840565","Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453",[49],"2008-07",[29,34],[1731],{"trials":1776,"activeCount":11},[],{"trials":1778,"activeCount":11},[],{"trials":1780,"activeCount":11},[],{"trials":1782,"activeCount":11},[],{"intervention":155,"totalTrials":1211,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1809,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1786,"activeCount":11},[],{"trials":1788,"activeCount":11},[1789,1793,1797,1801,1805],{"nctId":147,"briefTitle":148,"status":68,"phases":1790,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":1791,"interventions":1792},[49],[26],[120,155],{"nctId":157,"briefTitle":158,"status":68,"phases":1794,"primaryCompletion":160,"completion":160,"start":161,"enrollment":152,"conditions":1795,"interventions":1796},[49],[20],[120,155],{"nctId":995,"briefTitle":996,"status":68,"phases":1798,"primaryCompletion":998,"completion":998,"start":999,"enrollment":9,"conditions":1799,"interventions":1800},[49],[14],[918,155],{"nctId":1151,"briefTitle":1152,"status":68,"phases":1802,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":181,"conditions":1803,"interventions":1804},[49],[1157],[1121,1159],{"nctId":1676,"briefTitle":1677,"status":68,"phases":1806,"primaryCompletion":1679,"completion":1679,"start":1680,"enrollment":983,"conditions":1807,"interventions":1808},[49],[23],[1622,155],{"trials":1810,"activeCount":11},[],{"trials":1812,"activeCount":11},[],{"trials":1814,"activeCount":11},[],{"trials":1816,"activeCount":11},[],{"intervention":1270,"totalTrials":35,"cells":1818},{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1839,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1820,"activeCount":11},[],{"trials":1822,"activeCount":11},[1823,1831,1835],{"nctId":1824,"briefTitle":1825,"status":68,"phases":1826,"primaryCompletion":1827,"completion":1827,"start":1828,"enrollment":357,"conditions":1829,"interventions":1830},"NCT03093389","Tolerability and Steady-state Pharmacokinetics of BIA 6-512",[49],"2005-07-29","2005-05-11",[17],[1270],{"nctId":1302,"briefTitle":1303,"status":68,"phases":1832,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1833,"interventions":1834},[49],[17],[1270,1271,1283],{"nctId":1262,"briefTitle":1263,"status":68,"phases":1836,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1837,"interventions":1838},[49],[17],[1270,1271,1203],{"trials":1840,"activeCount":11},[],{"trials":1842,"activeCount":11},[],{"trials":1844,"activeCount":11},[],{"trials":1846,"activeCount":11},[],{"intervention":488,"totalTrials":35,"cells":1848},{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1865,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1850,"activeCount":11},[],{"trials":1852,"activeCount":11},[1853,1857,1861],{"nctId":1034,"briefTitle":1035,"status":68,"phases":1854,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":24,"conditions":1855,"interventions":1856},[49],[14],[918,488],{"nctId":482,"briefTitle":483,"status":68,"phases":1858,"primaryCompletion":278,"completion":485,"start":337,"enrollment":21,"conditions":1859,"interventions":1860},[49],[32],[441,488],{"nctId":1042,"briefTitle":1043,"status":68,"phases":1862,"primaryCompletion":1045,"completion":1045,"start":1046,"enrollment":9,"conditions":1863,"interventions":1864},[49],[14],[918,488],{"trials":1866,"activeCount":11},[],{"trials":1868,"activeCount":11},[],{"trials":1870,"activeCount":11},[],{"trials":1872,"activeCount":11},[],{"intervention":933,"totalTrials":8,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1887,"PHASE3":1889,"PHASE4":1891,"NA":1893},{"trials":1876,"activeCount":11},[],{"trials":1878,"activeCount":11},[1879,1883],{"nctId":925,"briefTitle":926,"status":68,"phases":1880,"primaryCompletion":928,"completion":928,"start":929,"enrollment":930,"conditions":1881,"interventions":1882},[49],[14],[918,933],{"nctId":299,"briefTitle":300,"status":68,"phases":1884,"primaryCompletion":302,"completion":294,"start":179,"enrollment":227,"conditions":1885,"interventions":1886},[49],[17],[120,305],{"trials":1888,"activeCount":11},[],{"trials":1890,"activeCount":11},[],{"trials":1892,"activeCount":11},[],{"trials":1894,"activeCount":11},[],{"intervention":940,"totalTrials":8,"cells":1896},{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1898,"activeCount":11},[],{"trials":1900,"activeCount":11},[1901,1905],{"nctId":935,"briefTitle":936,"status":68,"phases":1902,"primaryCompletion":929,"completion":929,"start":493,"enrollment":495,"conditions":1903,"interventions":1904},[49],[14],[918,940],{"nctId":448,"briefTitle":449,"status":450,"phases":1906,"primaryCompletion":452,"completion":452,"start":453,"enrollment":217,"conditions":1907,"interventions":1908},[49],[14],[441,456],{"trials":1910,"activeCount":11},[],{"trials":1912,"activeCount":11},[],{"trials":1914,"activeCount":11},[],{"trials":1916,"activeCount":11},[],{"intervention":211,"totalTrials":8,"cells":1918},{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1931,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1920,"activeCount":11},[],{"trials":1922,"activeCount":11},[1923,1927],{"nctId":203,"briefTitle":204,"status":68,"phases":1924,"primaryCompletion":206,"completion":207,"start":208,"enrollment":199,"conditions":1925,"interventions":1926},[49],[17],[211,120],{"nctId":315,"briefTitle":316,"status":68,"phases":1928,"primaryCompletion":206,"completion":318,"start":208,"enrollment":319,"conditions":1929,"interventions":1930},[49],[17],[120,322],{"trials":1932,"activeCount":11},[],{"trials":1934,"activeCount":11},[],{"trials":1936,"activeCount":11},[],{"trials":1938,"activeCount":11},[],{"intervention":281,"totalTrials":8,"cells":1940},{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1942,"activeCount":11},[],{"trials":1944,"activeCount":11},[1945,1949],{"nctId":1252,"briefTitle":1253,"status":68,"phases":1946,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":170,"conditions":1947,"interventions":1948},[49],[17],[281,1203,1259,1260],{"nctId":275,"briefTitle":276,"status":68,"phases":1950,"primaryCompletion":278,"completion":278,"start":131,"enrollment":181,"conditions":1951,"interventions":1952},[49],[26],[120,281],{"trials":1954,"activeCount":11},[],{"trials":1956,"activeCount":11},[],{"trials":1958,"activeCount":11},[],{"trials":1960,"activeCount":11},[],{"intervention":691,"totalTrials":8,"cells":1962},{"EARLY_PHASE1":1963,"PHASE1":1965,"PHASE2":1981,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1964,"activeCount":11},[],{"trials":1966,"activeCount":11},[1967,1971],{"nctId":684,"briefTitle":685,"status":68,"phases":1968,"primaryCompletion":206,"completion":687,"start":208,"enrollment":688,"conditions":1969,"interventions":1970},[49],[17],[691,173,331,692,693],{"nctId":1972,"briefTitle":1973,"status":68,"phases":1974,"primaryCompletion":207,"completion":207,"start":206,"enrollment":1975,"conditions":1976,"interventions":1977},"NCT02169414","Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics",[49],74,[26],[691,1978,1979,1980],"BIA 9-1067 25 mg","levodopa\u002Fcarbidopa 100\u002F25","levodopa\u002Fbenserazide 100\u002F25 mg",{"trials":1982,"activeCount":11},[],{"trials":1984,"activeCount":11},[],{"trials":1986,"activeCount":11},[],{"trials":1988,"activeCount":11},[],{"intervention":1271,"totalTrials":8,"cells":1990},{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":2003,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1992,"activeCount":11},[],{"trials":1994,"activeCount":11},[1995,1999],{"nctId":1302,"briefTitle":1303,"status":68,"phases":1996,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1997,"interventions":1998},[49],[17],[1270,1271,1283],{"nctId":1262,"briefTitle":1263,"status":68,"phases":2000,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":2001,"interventions":2002},[49],[17],[1270,1271,1203],{"trials":2004,"activeCount":11},[],{"trials":2006,"activeCount":11},[],{"trials":2008,"activeCount":11},[],{"trials":2010,"activeCount":11},[],{"intervention":1135,"totalTrials":98,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2021,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2014,"activeCount":11},[],{"trials":2016,"activeCount":11},[2017],{"nctId":1129,"briefTitle":1130,"status":68,"phases":2018,"primaryCompletion":601,"completion":601,"start":1132,"enrollment":1030,"conditions":2019,"interventions":2020},[49],[26],[1121,1135],{"trials":2022,"activeCount":11},[],{"trials":2024,"activeCount":11},[],{"trials":2026,"activeCount":11},[],{"trials":2028,"activeCount":11},[],{"intervention":2030,"totalTrials":98,"cells":2031},"BIA 2-093 3000 mg once daily",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2043,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2033,"activeCount":11},[],{"trials":2035,"activeCount":11},[2036],{"nctId":2037,"briefTitle":2038,"status":68,"phases":2039,"primaryCompletion":602,"completion":602,"start":1154,"enrollment":181,"conditions":2040,"interventions":2041},"NCT01879332","A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers",[49],[14],[2030,2042],"BIA 2-093 3600 mg once daily",{"trials":2044,"activeCount":11},[],{"trials":2046,"activeCount":11},[],{"trials":2048,"activeCount":11},[],{"trials":2050,"activeCount":11},[],{"intervention":2042,"totalTrials":98,"cells":2052},{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2061,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2054,"activeCount":11},[],{"trials":2056,"activeCount":11},[2057],{"nctId":2037,"briefTitle":2038,"status":68,"phases":2058,"primaryCompletion":602,"completion":602,"start":1154,"enrollment":181,"conditions":2059,"interventions":2060},[49],[14],[2030,2042],{"trials":2062,"activeCount":11},[],{"trials":2064,"activeCount":11},[],{"trials":2066,"activeCount":11},[],{"trials":2068,"activeCount":11},[],{"intervention":145,"totalTrials":98,"cells":2070},{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2079,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2072,"activeCount":11},[],{"trials":2074,"activeCount":11},[2075],{"nctId":137,"briefTitle":138,"status":68,"phases":2076,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":2077,"interventions":2078},[49],[17],[145,120],{"trials":2080,"activeCount":11},[],{"trials":2082,"activeCount":11},[],{"trials":2084,"activeCount":11},[],{"trials":2086,"activeCount":11},[],{"intervention":2088,"totalTrials":98,"cells":2089},"Madopar® HBS 125",{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2106,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2091,"activeCount":11},[],{"trials":2093,"activeCount":11},[2094],{"nctId":2095,"briefTitle":2096,"status":68,"phases":2097,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":152,"conditions":2100,"interventions":2101},"NCT03091543","Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics",[49],"2004-07-23","2004-05-04",[17],[2088,2102,2103,2104,2105],"BIA 6-512 25 mg dose","BIA 6-512 50 mg dose","BIA 6-512 100 mg dose","BIA 6-512 200 mg dose",{"trials":2107,"activeCount":11},[],{"trials":2109,"activeCount":11},[],{"trials":2111,"activeCount":11},[],{"trials":2113,"activeCount":11},[],{"intervention":2102,"totalTrials":98,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2117,"activeCount":11},[],{"trials":2119,"activeCount":11},[2120],{"nctId":2095,"briefTitle":2096,"status":68,"phases":2121,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":152,"conditions":2122,"interventions":2123},[49],[17],[2088,2102,2103,2104,2105],{"trials":2125,"activeCount":11},[],{"trials":2127,"activeCount":11},[],{"trials":2129,"activeCount":11},[],{"trials":2131,"activeCount":11},[],{"intervention":2103,"totalTrials":98,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2142,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2135,"activeCount":11},[],{"trials":2137,"activeCount":11},[2138],{"nctId":2095,"briefTitle":2096,"status":68,"phases":2139,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":152,"conditions":2140,"interventions":2141},[49],[17],[2088,2102,2103,2104,2105],{"trials":2143,"activeCount":11},[],{"trials":2145,"activeCount":11},[],{"trials":2147,"activeCount":11},[],{"trials":2149,"activeCount":11},[],{"intervention":2104,"totalTrials":98,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2160,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2153,"activeCount":11},[],{"trials":2155,"activeCount":11},[2156],{"nctId":2095,"briefTitle":2096,"status":68,"phases":2157,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":152,"conditions":2158,"interventions":2159},[49],[17],[2088,2102,2103,2104,2105],{"trials":2161,"activeCount":11},[],{"trials":2163,"activeCount":11},[],{"trials":2165,"activeCount":11},[],{"trials":2167,"activeCount":11},[],{"intervention":2105,"totalTrials":98,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2178,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":11},[],{"trials":2173,"activeCount":11},[2174],{"nctId":2095,"briefTitle":2096,"status":68,"phases":2175,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":152,"conditions":2176,"interventions":2177},[49],[17],[2088,2102,2103,2104,2105],{"trials":2179,"activeCount":11},[],{"trials":2181,"activeCount":11},[],{"trials":2183,"activeCount":11},[],{"trials":2185,"activeCount":11},[],{"intervention":2187,"totalTrials":98,"cells":2188},"[14C]-BIA 9-1067",{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2208},{"trials":2190,"activeCount":11},[],{"trials":2192,"activeCount":11},[2193],{"nctId":2194,"briefTitle":2195,"status":68,"phases":2196,"primaryCompletion":2197,"completion":2197,"start":2198,"enrollment":2199,"conditions":2200,"interventions":2201},"NCT03119194","Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067",[49],"2017-04-27","2017-01-27",7,[17],[2187],{"trials":2203,"activeCount":11},[],{"trials":2205,"activeCount":11},[],{"trials":2207,"activeCount":11},[],{"trials":2209,"activeCount":11},[],{"intervention":2211,"totalTrials":98,"cells":2212},"BIA-5-453",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2223,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2214,"activeCount":11},[],{"trials":2216,"activeCount":11},[2217],{"nctId":2218,"briefTitle":2219,"status":68,"phases":2220,"primaryCompletion":198,"completion":198,"start":131,"enrollment":217,"conditions":2221,"interventions":2222},"NCT03014375","Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites",[49],[29,1758],[2211],{"trials":2224,"activeCount":11},[],{"trials":2226,"activeCount":11},[],{"trials":2228,"activeCount":11},[],{"trials":2230,"activeCount":11},[],{"intervention":1637,"totalTrials":98,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2241,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2234,"activeCount":11},[],{"trials":2236,"activeCount":11},[2237],{"nctId":1629,"briefTitle":1630,"status":68,"phases":2238,"primaryCompletion":1632,"completion":1632,"start":1633,"enrollment":1634,"conditions":2239,"interventions":2240},[49],[23],[1622,1637],{"trials":2242,"activeCount":11},[],{"trials":2244,"activeCount":11},[],{"trials":2246,"activeCount":11},[],{"trials":2248,"activeCount":11},[],{"intervention":193,"totalTrials":98,"cells":2250},{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2259,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2252,"activeCount":11},[],{"trials":2254,"activeCount":11},[2255],{"nctId":185,"briefTitle":186,"status":68,"phases":2256,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":2257,"interventions":2258},[49],[26],[120,193],{"trials":2260,"activeCount":11},[],{"trials":2262,"activeCount":11},[],{"trials":2264,"activeCount":11},[],{"trials":2266,"activeCount":11},[],{"intervention":969,"totalTrials":98,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2277,"PHASE3":2279,"PHASE4":2281,"NA":2283},{"trials":2270,"activeCount":11},[],{"trials":2272,"activeCount":11},[2273],{"nctId":964,"briefTitle":965,"status":68,"phases":2274,"primaryCompletion":602,"completion":602,"start":493,"enrollment":495,"conditions":2275,"interventions":2276},[49],[14],[918,969],{"trials":2278,"activeCount":11},[],{"trials":2280,"activeCount":11},[],{"trials":2282,"activeCount":11},[],{"trials":2284,"activeCount":11},[],{"intervention":977,"totalTrials":98,"cells":2286},{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2295,"PHASE3":2297,"PHASE4":2299,"NA":2301},{"trials":2288,"activeCount":11},[],{"trials":2290,"activeCount":11},[2291],{"nctId":971,"briefTitle":972,"status":68,"phases":2292,"primaryCompletion":974,"completion":974,"start":952,"enrollment":152,"conditions":2293,"interventions":2294},[49],[14],[918,977],{"trials":2296,"activeCount":11},[],{"trials":2298,"activeCount":11},[],{"trials":2300,"activeCount":11},[],{"trials":2302,"activeCount":11},[],{"intervention":1646,"totalTrials":98,"cells":2304},{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2313,"PHASE3":2315,"PHASE4":2317,"NA":2319},{"trials":2306,"activeCount":11},[],{"trials":2308,"activeCount":11},[2309],{"nctId":1639,"briefTitle":1640,"status":68,"phases":2310,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":152,"conditions":2311,"interventions":2312},[49],[23],[1622,1646],{"trials":2314,"activeCount":11},[],{"trials":2316,"activeCount":11},[],{"trials":2318,"activeCount":11},[],{"trials":2320,"activeCount":11},[],{"intervention":1259,"totalTrials":98,"cells":2322},{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2331,"PHASE3":2333,"PHASE4":2335,"NA":2337},{"trials":2324,"activeCount":11},[],{"trials":2326,"activeCount":11},[2327],{"nctId":1252,"briefTitle":1253,"status":68,"phases":2328,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":170,"conditions":2329,"interventions":2330},[49],[17],[281,1203,1259,1260],{"trials":2332,"activeCount":11},[],{"trials":2334,"activeCount":11},[],{"trials":2336,"activeCount":11},[],{"trials":2338,"activeCount":11},[],{"intervention":1260,"totalTrials":98,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2342,"activeCount":11},[],{"trials":2344,"activeCount":11},[2345],{"nctId":1252,"briefTitle":1253,"status":68,"phases":2346,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":170,"conditions":2347,"interventions":2348},[49],[17],[281,1203,1259,1260],{"trials":2350,"activeCount":11},[],{"trials":2352,"activeCount":11},[],{"trials":2354,"activeCount":11},[],{"trials":2356,"activeCount":11},[],{"intervention":472,"totalTrials":98,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2360,"activeCount":11},[],{"trials":2362,"activeCount":11},[2363],{"nctId":466,"briefTitle":467,"status":68,"phases":2364,"primaryCompletion":224,"completion":131,"start":226,"enrollment":152,"conditions":2365,"interventions":2366},[49],[470],[472,441],{"trials":2368,"activeCount":11},[],{"trials":2370,"activeCount":11},[],{"trials":2372,"activeCount":11},[],{"trials":2374,"activeCount":11},[],{"intervention":238,"totalTrials":98,"cells":2376},{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2385,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2378,"activeCount":11},[],{"trials":2380,"activeCount":11},[2381],{"nctId":231,"briefTitle":232,"status":68,"phases":2382,"primaryCompletion":150,"completion":234,"start":151,"enrollment":235,"conditions":2383,"interventions":2384},[49],[17],[120,238],{"trials":2386,"activeCount":11},[],{"trials":2388,"activeCount":11},[],{"trials":2390,"activeCount":11},[],{"trials":2392,"activeCount":11},[],{"intervention":1664,"totalTrials":98,"cells":2394},{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2403,"PHASE3":2405,"PHASE4":2407,"NA":2409},{"trials":2396,"activeCount":11},[],{"trials":2398,"activeCount":11},[2399],{"nctId":1657,"briefTitle":1658,"status":68,"phases":2400,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":152,"conditions":2401,"interventions":2402},[49],[23],[1622,1664],{"trials":2404,"activeCount":11},[],{"trials":2406,"activeCount":11},[],{"trials":2408,"activeCount":11},[],{"trials":2410,"activeCount":11},[],{"intervention":480,"totalTrials":98,"cells":2412},{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2421,"PHASE3":2423,"PHASE4":2425,"NA":2427},{"trials":2414,"activeCount":11},[],{"trials":2416,"activeCount":11},[2417],{"nctId":474,"briefTitle":475,"status":68,"phases":2418,"primaryCompletion":327,"completion":327,"start":151,"enrollment":477,"conditions":2419,"interventions":2420},[49],[14],[441,480],{"trials":2422,"activeCount":11},[],{"trials":2424,"activeCount":11},[],{"trials":2426,"activeCount":11},[],{"trials":2428,"activeCount":11},[],{"intervention":1673,"totalTrials":98,"cells":2430},{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2439,"PHASE3":2441,"PHASE4":2443,"NA":2445},{"trials":2432,"activeCount":11},[],{"trials":2434,"activeCount":11},[2435],{"nctId":1666,"briefTitle":1667,"status":68,"phases":2436,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":1634,"conditions":2437,"interventions":2438},[49],[23],[1622,1673,1674],{"trials":2440,"activeCount":11},[],{"trials":2442,"activeCount":11},[],{"trials":2444,"activeCount":11},[],{"trials":2446,"activeCount":11},[],{"intervention":1674,"totalTrials":98,"cells":2448},{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2457,"PHASE3":2459,"PHASE4":2461,"NA":2463},{"trials":2450,"activeCount":11},[],{"trials":2452,"activeCount":11},[2453],{"nctId":1666,"briefTitle":1667,"status":68,"phases":2454,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":1634,"conditions":2455,"interventions":2456},[49],[23],[1622,1673,1674],{"trials":2458,"activeCount":11},[],{"trials":2460,"activeCount":11},[],{"trials":2462,"activeCount":11},[],{"trials":2464,"activeCount":11},[],{"intervention":256,"totalTrials":98,"cells":2466},{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2475,"PHASE3":2477,"PHASE4":2479,"NA":2481},{"trials":2468,"activeCount":11},[],{"trials":2470,"activeCount":11},[2471],{"nctId":248,"briefTitle":249,"status":68,"phases":2472,"primaryCompletion":251,"completion":206,"start":252,"enrollment":253,"conditions":2473,"interventions":2474},[49],[17],[120,256],{"trials":2476,"activeCount":11},[],{"trials":2478,"activeCount":11},[],{"trials":2480,"activeCount":11},[],{"trials":2482,"activeCount":11},[],{"intervention":2484,"totalTrials":98,"cells":2485},"400 mg BIA 5-1058",{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2499,"PHASE3":2501,"PHASE4":2503,"NA":2505},{"trials":2487,"activeCount":11},[],{"trials":2489,"activeCount":11},[2490],{"nctId":2491,"briefTitle":2492,"status":68,"phases":2493,"primaryCompletion":2494,"completion":2494,"start":2495,"enrollment":2496,"conditions":2497,"interventions":2498},"NCT04991181","Absorption, Distribution, Metabolism and Excretion of BIA 5-1058",[49],"2017-05-24","2017-03-31",15,[23],[2484],{"trials":2500,"activeCount":11},[],{"trials":2502,"activeCount":11},[],{"trials":2504,"activeCount":11},[],{"trials":2506,"activeCount":11},[],{"intervention":1178,"totalTrials":98,"cells":2508},{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2517,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2510,"activeCount":11},[],{"trials":2512,"activeCount":11},[2513],{"nctId":1170,"briefTitle":1171,"status":68,"phases":2514,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":2515,"interventions":2516},[49],[20],[1121,1178],{"trials":2518,"activeCount":11},[],{"trials":2520,"activeCount":11},[],{"trials":2522,"activeCount":11},[],{"trials":2524,"activeCount":11},[],{"intervention":692,"totalTrials":98,"cells":2526},{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2528,"activeCount":11},[],{"trials":2530,"activeCount":11},[2531],{"nctId":684,"briefTitle":685,"status":68,"phases":2532,"primaryCompletion":206,"completion":687,"start":208,"enrollment":688,"conditions":2533,"interventions":2534},[49],[17],[691,173,331,692,693],{"trials":2536,"activeCount":11},[],{"trials":2538,"activeCount":11},[],{"trials":2540,"activeCount":11},[],{"trials":2542,"activeCount":11},[],{"intervention":693,"totalTrials":98,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2553,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2546,"activeCount":11},[],{"trials":2548,"activeCount":11},[2549],{"nctId":684,"briefTitle":685,"status":68,"phases":2550,"primaryCompletion":206,"completion":687,"start":208,"enrollment":688,"conditions":2551,"interventions":2552},[49],[17],[691,173,331,692,693],{"trials":2554,"activeCount":11},[],{"trials":2556,"activeCount":11},[],{"trials":2558,"activeCount":11},[],{"trials":2560,"activeCount":11},[],{"intervention":498,"totalTrials":98,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2571,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2564,"activeCount":11},[],{"trials":2566,"activeCount":11},[2567],{"nctId":490,"briefTitle":491,"status":68,"phases":2568,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":2569,"interventions":2570},[49],[14],[441,498],{"trials":2572,"activeCount":11},[],{"trials":2574,"activeCount":11},[],{"trials":2576,"activeCount":11},[],{"trials":2578,"activeCount":11},[],{"intervention":2580,"totalTrials":98,"cells":2581},"eslicarbazepine acetate and Microginon®",{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2593,"PHASE3":2595,"PHASE4":2597,"NA":2599},{"trials":2583,"activeCount":11},[],{"trials":2585,"activeCount":11},[2586],{"nctId":2587,"briefTitle":2588,"status":68,"phases":2589,"primaryCompletion":337,"completion":337,"start":131,"enrollment":152,"conditions":2590,"interventions":2591},"NCT00898560","Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive",[49],[32],[2580,2592],"Microginon®",{"trials":2594,"activeCount":11},[],{"trials":2596,"activeCount":11},[],{"trials":2598,"activeCount":11},[],{"trials":2600,"activeCount":11},[],{"intervention":2592,"totalTrials":98,"cells":2602},{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2611,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2604,"activeCount":11},[],{"trials":2606,"activeCount":11},[2607],{"nctId":2587,"briefTitle":2588,"status":68,"phases":2608,"primaryCompletion":337,"completion":337,"start":131,"enrollment":152,"conditions":2609,"interventions":2610},[49],[32],[2580,2592],{"trials":2612,"activeCount":11},[],{"trials":2614,"activeCount":11},[],{"trials":2616,"activeCount":11},[],{"trials":2618,"activeCount":11},[],{"intervention":2620,"totalTrials":98,"cells":2621},"BIA 6-512 400 mg",{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2634,"PHASE3":2636,"PHASE4":2638,"NA":2640},{"trials":2623,"activeCount":11},[],{"trials":2625,"activeCount":11},[2626],{"nctId":2627,"briefTitle":2628,"status":68,"phases":2629,"primaryCompletion":2630,"completion":2630,"start":2631,"enrollment":199,"conditions":2632,"interventions":2633},"NCT03095092","Effect of Food on BIA 6-512 (Trans-resveratrol)",[49],"2005-07-07","2005-05-23",[17],[2620],{"trials":2635,"activeCount":11},[],{"trials":2637,"activeCount":11},[],{"trials":2639,"activeCount":11},[],{"trials":2641,"activeCount":11},[],{"intervention":288,"totalTrials":98,"cells":2643},{"EARLY_PHASE1":2644,"PHASE1":2646,"PHASE2":2652,"PHASE3":2654,"PHASE4":2656,"NA":2658},{"trials":2645,"activeCount":11},[],{"trials":2647,"activeCount":11},[2648],{"nctId":283,"briefTitle":284,"status":68,"phases":2649,"primaryCompletion":189,"completion":189,"start":198,"enrollment":24,"conditions":2650,"interventions":2651},[49],[26],[120,288],{"trials":2653,"activeCount":11},[],{"trials":2655,"activeCount":11},[],{"trials":2657,"activeCount":11},[],{"trials":2659,"activeCount":11},[],{"intervention":2661,"totalTrials":98,"cells":2662},"BIA 9-1067 non-micronized",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2674,"PHASE3":2676,"PHASE4":2678,"NA":2680},{"trials":2664,"activeCount":11},[],{"trials":2666,"activeCount":11},[2667],{"nctId":2668,"briefTitle":2669,"status":68,"phases":2670,"primaryCompletion":161,"completion":161,"start":270,"enrollment":310,"conditions":2671,"interventions":2672},"NCT02305316","Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone",[49],[17],[2661,2673],"BIA 9-1067 micronized",{"trials":2675,"activeCount":11},[],{"trials":2677,"activeCount":11},[],{"trials":2679,"activeCount":11},[],{"trials":2681,"activeCount":11},[],{"intervention":2673,"totalTrials":98,"cells":2683},{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2692,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2685,"activeCount":11},[],{"trials":2687,"activeCount":11},[2688],{"nctId":2668,"briefTitle":2669,"status":68,"phases":2689,"primaryCompletion":161,"completion":161,"start":270,"enrollment":310,"conditions":2690,"interventions":2691},[49],[17],[2661,2673],{"trials":2693,"activeCount":11},[],{"trials":2695,"activeCount":11},[],{"trials":2697,"activeCount":11},[],{"trials":2699,"activeCount":11},[],{"intervention":2701,"totalTrials":98,"cells":2702},"OPC",{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2714,"PHASE3":2716,"PHASE4":2718,"NA":2720},{"trials":2704,"activeCount":11},[],{"trials":2706,"activeCount":11},[2707],{"nctId":2708,"briefTitle":2709,"status":68,"phases":2710,"primaryCompletion":2711,"completion":2711,"start":367,"enrollment":30,"conditions":2712,"interventions":2713},"NCT02169427","An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites",[49],"2011-07",[26],[2701],{"trials":2715,"activeCount":11},[],{"trials":2717,"activeCount":11},[],{"trials":2719,"activeCount":11},[],{"trials":2721,"activeCount":11},[],{"intervention":313,"totalTrials":98,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2732,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2725,"activeCount":11},[],{"trials":2727,"activeCount":11},[2728],{"nctId":307,"briefTitle":308,"status":68,"phases":2729,"primaryCompletion":269,"completion":269,"start":161,"enrollment":310,"conditions":2730,"interventions":2731},[49],[20],[120,313],{"trials":2733,"activeCount":11},[],{"trials":2735,"activeCount":11},[],{"trials":2737,"activeCount":11},[],{"trials":2739,"activeCount":11},[],{"intervention":1185,"totalTrials":98,"cells":2741},{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2750,"PHASE3":2752,"PHASE4":2754,"NA":2756},{"trials":2743,"activeCount":11},[],{"trials":2745,"activeCount":11},[2746],{"nctId":1180,"briefTitle":1181,"status":68,"phases":2747,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":253,"conditions":2748,"interventions":2749},[49],[20],[1121,1185],{"trials":2751,"activeCount":11},[],{"trials":2753,"activeCount":11},[],{"trials":2755,"activeCount":11},[],{"trials":2757,"activeCount":11},[],{"intervention":1713,"totalTrials":98,"cells":2759},{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2768,"PHASE3":2770,"PHASE4":2772,"NA":2774},{"trials":2761,"activeCount":11},[],{"trials":2763,"activeCount":11},[2764],{"nctId":1703,"briefTitle":1704,"status":68,"phases":2765,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":2766,"interventions":2767},[49],[1710,23,1711],[1622,1713],{"trials":2769,"activeCount":11},[],{"trials":2771,"activeCount":11},[],{"trials":2773,"activeCount":11},[],{"trials":2775,"activeCount":11},[],{"intervention":2777,"totalTrials":98,"cells":2778},"50 mg BIA 9 1067",{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2794,"PHASE3":2796,"PHASE4":2798,"NA":2800},{"trials":2780,"activeCount":11},[],{"trials":2782,"activeCount":11},[2783],{"nctId":2784,"briefTitle":2785,"status":68,"phases":2786,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":594,"conditions":2789,"interventions":2790},"NCT04265027","Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)",[49],"2018-07-24","2018-02-20",[17],[2777,2791,2792,2793],"25 mg BIA9 1067","50 mg Ongentys","25 mg Ongentys",{"trials":2795,"activeCount":11},[],{"trials":2797,"activeCount":11},[],{"trials":2799,"activeCount":11},[],{"trials":2801,"activeCount":11},[],{"intervention":2791,"totalTrials":98,"cells":2803},{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2812,"PHASE3":2814,"PHASE4":2816,"NA":2818},{"trials":2805,"activeCount":11},[],{"trials":2807,"activeCount":11},[2808],{"nctId":2784,"briefTitle":2785,"status":68,"phases":2809,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":594,"conditions":2810,"interventions":2811},[49],[17],[2777,2791,2792,2793],{"trials":2813,"activeCount":11},[],{"trials":2815,"activeCount":11},[],{"trials":2817,"activeCount":11},[],{"trials":2819,"activeCount":11},[],{"intervention":2792,"totalTrials":98,"cells":2821},{"EARLY_PHASE1":2822,"PHASE1":2824,"PHASE2":2830,"PHASE3":2832,"PHASE4":2834,"NA":2836},{"trials":2823,"activeCount":11},[],{"trials":2825,"activeCount":11},[2826],{"nctId":2784,"briefTitle":2785,"status":68,"phases":2827,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":594,"conditions":2828,"interventions":2829},[49],[17],[2777,2791,2792,2793],{"trials":2831,"activeCount":11},[],{"trials":2833,"activeCount":11},[],{"trials":2835,"activeCount":11},[],{"trials":2837,"activeCount":11},[],{"intervention":2793,"totalTrials":98,"cells":2839},{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2841,"activeCount":11},[],{"trials":2843,"activeCount":11},[2844],{"nctId":2784,"briefTitle":2785,"status":68,"phases":2845,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":594,"conditions":2846,"interventions":2847},[49],[17],[2777,2791,2792,2793],{"trials":2849,"activeCount":11},[],{"trials":2851,"activeCount":11},[],{"trials":2853,"activeCount":11},[],{"trials":2855,"activeCount":11},[],{"intervention":1064,"totalTrials":98,"cells":2857},{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2866,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2859,"activeCount":11},[],{"trials":2861,"activeCount":11},[2862],{"nctId":1058,"briefTitle":1059,"status":68,"phases":2863,"primaryCompletion":998,"completion":1061,"start":999,"enrollment":9,"conditions":2864,"interventions":2865},[49],[14],[918,1064],{"trials":2867,"activeCount":11},[],{"trials":2869,"activeCount":11},[],{"trials":2871,"activeCount":11},[],{"trials":2873,"activeCount":11},[],{"intervention":2875,"totalTrials":98,"cells":2876},"BIA 2-093 - 1800 mg",{"EARLY_PHASE1":2877,"PHASE1":2879,"PHASE2":2889,"PHASE3":2891,"PHASE4":2893,"NA":2895},{"trials":2878,"activeCount":11},[],{"trials":2880,"activeCount":11},[2881],{"nctId":2882,"briefTitle":2883,"status":68,"phases":2884,"primaryCompletion":583,"completion":583,"start":2885,"enrollment":253,"conditions":2886,"interventions":2887},"NCT01879345","A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers",[49],"2004-10",[14],[2875,2888],"BIA 2-093 - 2400 mg",{"trials":2890,"activeCount":11},[],{"trials":2892,"activeCount":11},[],{"trials":2894,"activeCount":11},[],{"trials":2896,"activeCount":11},[],{"intervention":2888,"totalTrials":98,"cells":2898},{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2907,"PHASE3":2909,"PHASE4":2911,"NA":2913},{"trials":2900,"activeCount":11},[],{"trials":2902,"activeCount":11},[2903],{"nctId":2882,"briefTitle":2883,"status":68,"phases":2904,"primaryCompletion":583,"completion":583,"start":2885,"enrollment":253,"conditions":2905,"interventions":2906},[49],[14],[2875,2888],{"trials":2908,"activeCount":11},[],{"trials":2910,"activeCount":11},[],{"trials":2912,"activeCount":11},[],{"trials":2914,"activeCount":11},[],{"intervention":1071,"totalTrials":98,"cells":2916},{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2925,"PHASE3":2927,"PHASE4":2929,"NA":2931},{"trials":2918,"activeCount":11},[],{"trials":2920,"activeCount":11},[2921],{"nctId":1066,"briefTitle":1067,"status":68,"phases":2922,"primaryCompletion":224,"completion":224,"start":226,"enrollment":152,"conditions":2923,"interventions":2924},[49],[14],[918,1071],{"trials":2926,"activeCount":11},[],{"trials":2928,"activeCount":11},[],{"trials":2930,"activeCount":11},[],{"trials":2932,"activeCount":11},[],{"intervention":1079,"totalTrials":98,"cells":2934},{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2943,"PHASE3":2945,"PHASE4":2947,"NA":2949},{"trials":2936,"activeCount":11},[],{"trials":2938,"activeCount":11},[2939],{"nctId":1073,"briefTitle":1074,"status":68,"phases":2940,"primaryCompletion":1076,"completion":1076,"start":951,"enrollment":495,"conditions":2941,"interventions":2942},[49],[14],[918,1079,1080],{"trials":2944,"activeCount":11},[],{"trials":2946,"activeCount":11},[],{"trials":2948,"activeCount":11},[],{"trials":2950,"activeCount":11},[],{"intervention":1080,"totalTrials":98,"cells":2952},{"EARLY_PHASE1":2953,"PHASE1":2955,"PHASE2":2961,"PHASE3":2963,"PHASE4":2965,"NA":2967},{"trials":2954,"activeCount":11},[],{"trials":2956,"activeCount":11},[2957],{"nctId":1073,"briefTitle":1074,"status":68,"phases":2958,"primaryCompletion":1076,"completion":1076,"start":951,"enrollment":495,"conditions":2959,"interventions":2960},[49],[14],[918,1079,1080],{"trials":2962,"activeCount":11},[],{"trials":2964,"activeCount":11},[],{"trials":2966,"activeCount":11},[],{"trials":2968,"activeCount":11},[],{"intervention":332,"totalTrials":98,"cells":2970},{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2979,"PHASE3":2981,"PHASE4":2983,"NA":2985},{"trials":2972,"activeCount":11},[],{"trials":2974,"activeCount":11},[2975],{"nctId":324,"briefTitle":325,"status":68,"phases":2976,"primaryCompletion":327,"completion":180,"start":252,"enrollment":328,"conditions":2977,"interventions":2978},[49],[17],[120,331,332],{"trials":2980,"activeCount":11},[],{"trials":2982,"activeCount":11},[],{"trials":2984,"activeCount":11},[],{"trials":2986,"activeCount":11},[],{"intervention":1978,"totalTrials":98,"cells":2988},{"EARLY_PHASE1":2989,"PHASE1":2991,"PHASE2":2997,"PHASE3":2999,"PHASE4":3001,"NA":3003},{"trials":2990,"activeCount":11},[],{"trials":2992,"activeCount":11},[2993],{"nctId":1972,"briefTitle":1973,"status":68,"phases":2994,"primaryCompletion":207,"completion":207,"start":206,"enrollment":1975,"conditions":2995,"interventions":2996},[49],[26],[691,1978,1979,1980],{"trials":2998,"activeCount":11},[],{"trials":3000,"activeCount":11},[],{"trials":3002,"activeCount":11},[],{"trials":3004,"activeCount":11},[],{"intervention":1979,"totalTrials":98,"cells":3006},{"EARLY_PHASE1":3007,"PHASE1":3009,"PHASE2":3015,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":3008,"activeCount":11},[],{"trials":3010,"activeCount":11},[3011],{"nctId":1972,"briefTitle":1973,"status":68,"phases":3012,"primaryCompletion":207,"completion":207,"start":206,"enrollment":1975,"conditions":3013,"interventions":3014},[49],[26],[691,1978,1979,1980],{"trials":3016,"activeCount":11},[],{"trials":3018,"activeCount":11},[],{"trials":3020,"activeCount":11},[],{"trials":3022,"activeCount":11},[],{"intervention":1980,"totalTrials":98,"cells":3024},{"EARLY_PHASE1":3025,"PHASE1":3027,"PHASE2":3033,"PHASE3":3035,"PHASE4":3037,"NA":3039},{"trials":3026,"activeCount":11},[],{"trials":3028,"activeCount":11},[3029],{"nctId":1972,"briefTitle":1973,"status":68,"phases":3030,"primaryCompletion":207,"completion":207,"start":206,"enrollment":1975,"conditions":3031,"interventions":3032},[49],[26],[691,1978,1979,1980],{"trials":3034,"activeCount":11},[],{"trials":3036,"activeCount":11},[],{"trials":3038,"activeCount":11},[],{"trials":3040,"activeCount":11},[],{"intervention":3042,"totalTrials":98,"cells":3043},"400 mg of BIA 5-1058",{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3057,"PHASE3":3059,"PHASE4":3061,"NA":3063},{"trials":3045,"activeCount":11},[],{"trials":3047,"activeCount":11},[3048],{"nctId":3049,"briefTitle":3050,"status":68,"phases":3051,"primaryCompletion":3052,"completion":3052,"start":3053,"enrollment":2199,"conditions":3054,"interventions":3056},"NCT04069130","Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058",[49],"2019-05-02","2019-01-22",[3055],"Cardiovascular Diseases",[3042],{"trials":3058,"activeCount":11},[],{"trials":3060,"activeCount":11},[],{"trials":3062,"activeCount":11},[],{"trials":3064,"activeCount":11},[],{"intervention":3066,"totalTrials":98,"cells":3067},"200 mg BIA 6-512",{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3080,"PHASE3":3082,"PHASE4":3084,"NA":3086},{"trials":3069,"activeCount":11},[],{"trials":3071,"activeCount":11},[3072],{"nctId":3073,"briefTitle":3074,"status":68,"phases":3075,"primaryCompletion":3076,"completion":3076,"start":3077,"enrollment":319,"conditions":3078,"interventions":3079},"NCT03095105","Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects",[49],"2006-03-02","2006-01-24",[17],[3066],{"trials":3081,"activeCount":11},[],{"trials":3083,"activeCount":11},[],{"trials":3085,"activeCount":11},[],{"trials":3087,"activeCount":11},[],{"intervention":340,"totalTrials":98,"cells":3089},{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3098,"PHASE3":3100,"PHASE4":3102,"NA":3104},{"trials":3091,"activeCount":11},[],{"trials":3093,"activeCount":11},[3094],{"nctId":334,"briefTitle":335,"status":68,"phases":3095,"primaryCompletion":337,"completion":337,"start":131,"enrollment":181,"conditions":3096,"interventions":3097},[49],[26],[120,340],{"trials":3099,"activeCount":11},[],{"trials":3101,"activeCount":11},[],{"trials":3103,"activeCount":11},[],{"trials":3105,"activeCount":11},[],{"intervention":1096,"totalTrials":98,"cells":3107},{"EARLY_PHASE1":3108,"PHASE1":3110,"PHASE2":3116,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3109,"activeCount":11},[],{"trials":3111,"activeCount":11},[3112],{"nctId":1090,"briefTitle":1091,"status":68,"phases":3113,"primaryCompletion":208,"completion":208,"start":150,"enrollment":1093,"conditions":3114,"interventions":3115},[49],[14],[918,1096],{"trials":3117,"activeCount":11},[],{"trials":3119,"activeCount":11},[],{"trials":3121,"activeCount":11},[],{"trials":3123,"activeCount":11},[],{"intervention":419,"totalTrials":1211,"cells":3125},{"EARLY_PHASE1":3126,"PHASE1":3128,"PHASE2":3146,"PHASE3":3148,"PHASE4":3150,"NA":3164},{"trials":3127,"activeCount":11},[],{"trials":3129,"activeCount":11},[3130,3138],{"nctId":3131,"briefTitle":3132,"status":68,"phases":3133,"primaryCompletion":3134,"completion":3134,"start":3135,"enrollment":310,"conditions":3136,"interventions":3137},"NCT03116308","Effect of Food on Opicapone",[49],"2015-01-28","2014-11-21",[17],[419],{"nctId":3139,"briefTitle":3140,"status":68,"phases":3141,"primaryCompletion":3142,"completion":3142,"start":3143,"enrollment":271,"conditions":3144,"interventions":3145},"NCT03116295","Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone",[49],"2017-08-28","2017-06-20",[17],[419],{"trials":3147,"activeCount":11},[],{"trials":3149,"activeCount":11},[],{"trials":3151,"activeCount":11},[3152,3156],{"nctId":411,"briefTitle":412,"status":68,"phases":3153,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":3154,"interventions":3155},[52],[17],[419,398],{"nctId":3157,"briefTitle":3158,"status":68,"phases":3159,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":190,"conditions":3162,"interventions":3163},"NCT04986995","OpicApone Sleep dISorder",[52],"2023-03-29","2021-06-09",[17],[419],{"trials":3165,"activeCount":11},[3166],{"nctId":3167,"briefTitle":3168,"status":68,"phases":3169,"primaryCompletion":3170,"completion":3170,"start":3171,"enrollment":1267,"conditions":3172,"interventions":3173},"NCT03959540","Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease",[],"2021-05-11","2020-04-28",[17],[419,3174],"Levodopa (L-DOPA) + Standard care",{"intervention":3176,"totalTrials":98,"cells":3177},"ESL",{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3179,"activeCount":11},[],{"trials":3181,"activeCount":11},[],{"trials":3183,"activeCount":11},[],{"trials":3185,"activeCount":11},[],{"trials":3187,"activeCount":11},[],{"trials":3189,"activeCount":11},[3190],{"nctId":3191,"briefTitle":3192,"status":68,"phases":3193,"primaryCompletion":3194,"completion":3194,"start":505,"enrollment":271,"conditions":3195,"interventions":3196},"NCT01532726","Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)",[],"2014-09",[14],[3176],{"intervention":3174,"totalTrials":98,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3205,"PHASE4":3207,"NA":3209},{"trials":3200,"activeCount":11},[],{"trials":3202,"activeCount":11},[],{"trials":3204,"activeCount":11},[],{"trials":3206,"activeCount":11},[],{"trials":3208,"activeCount":11},[],{"trials":3210,"activeCount":11},[3211],{"nctId":3167,"briefTitle":3168,"status":68,"phases":3212,"primaryCompletion":3170,"completion":3170,"start":3171,"enrollment":1267,"conditions":3213,"interventions":3214},[],[17],[419,3174]]